Yvette L Kasamon1, Richard L Wahl, Lode J Swinnen. 1. Divisions of Hematologic Malignancies and Nuclear Medicine, Johns Hopkins Medical Institutions, Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Room 207, Baltimore, MD 21231, USA.
Abstract
PURPOSE OF REVIEW: Functional metabolic imaging through fluorine-18 fluorodeoxyglucose positron emission tomography has recently come to the forefront in the management of various solid and hematologic malignancies. This review summarizes the developments in risk assessment through positron emission tomography in patients with lymphoma and the implications for management. RECENT FINDINGS: In addition to improving staging and response assessment, positron emission tomography has emerged as a strong prognostic tool in patients with aggressive lymphomas. A positron emission tomographic scan performed after only a few cycles of chemotherapy can accurately predict relapse risk, and most studied patients with abnormal positron emission tomographic scans have had distinctly poorer clinical outcomes than patients with negative scans. SUMMARY: With confirmation of these findings, a more individualized, risk-adapted approach to the treatment of aggressive lymphomas will be feasible. Early identification of high-risk patients through the combination of positron emission tomography and existing prognostic indices could lead to earlier implementation of intensive therapies and improved clinical outcomes.
PURPOSE OF REVIEW: Functional metabolic imaging through fluorine-18 fluorodeoxyglucose positron emission tomography has recently come to the forefront in the management of various solid and hematologic malignancies. This review summarizes the developments in risk assessment through positron emission tomography in patients with lymphoma and the implications for management. RECENT FINDINGS: In addition to improving staging and response assessment, positron emission tomography has emerged as a strong prognostic tool in patients with aggressive lymphomas. A positron emission tomographic scan performed after only a few cycles of chemotherapy can accurately predict relapse risk, and most studied patients with abnormal positron emission tomographic scans have had distinctly poorer clinical outcomes than patients with negative scans. SUMMARY: With confirmation of these findings, a more individualized, risk-adapted approach to the treatment of aggressive lymphomas will be feasible. Early identification of high-risk patients through the combination of positron emission tomography and existing prognostic indices could lead to earlier implementation of intensive therapies and improved clinical outcomes.
Authors: Craig H Moskowitz; Joachim Yahalom; Andrew D Zelenetz; Zhigang Zhang; Daniel Filippa; Julie Teruya-Feldstein; Tarun Kewalramani; Alison J Moskowitz; Robert David Rice; Jocelyn Maragulia; Jill Vanak; Tanya Trippett; Paul Hamlin; Steven Horowitz; Ariela Noy; Owen A O'Connor; Carol Portlock; David Straus; Stephen D Nimer Journal: Br J Haematol Date: 2010-01-18 Impact factor: 6.998
Authors: Phillip H Kuo; Bruce L McClennan; Kacie Carlson; Lynn D Wilson; Richard L Edelson; Peter W Heald; Michael Girardi Journal: Mol Imaging Biol Date: 2008-01-15 Impact factor: 3.488
Authors: Fernando Arias-Mendoza; Geoffrey S Payne; Kristen Zakian; Marion Stubbs; Owen A O'Connor; Hamed Mojahed; Mitchell R Smith; Adam J Schwarz; Amita Shukla-Dave; Franklyn Howe; Harish Poptani; Seung-Cheol Lee; Ruth Pettengel; Steven J Schuster; David Cunningham; Arend Heerschap; Jerry D Glickson; John R Griffiths; Jason A Koutcher; Martin O Leach; Truman R Brown Journal: Acad Radiol Date: 2013-09 Impact factor: 3.173